Researchers

no image

MURATA Daiki
Assistant Professor A in Medical School
Faculty Department of Medicine
Researchmap https://researchmap.jp/muratad221217

Education and Career

Education

  • 2013/04 - 2019/03 , Saga University, School of Medicine,
  • 2025/04 - Today , Kindai University, Graduate School of Medical Sciences,

Academic & Professional Experience

  • Apr. 2025 - Today , Kindai University Faculty of Medicine, Department of Medical Oncology
  • Apr. 2024 - Mar. 2025 , Kurume University School of Medicine Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine
  • Oct. 2022 - Mar. 2024 , Saga-Ken Medical Centre Koseikan Division of Respiratory Medicine
  • Apr. 2021 - Sep. 2022 , Kurume University School of Medicine Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine
  • Apr. 2019 - Mar. 2021 , National Hospital Organization, Kure Medical Center and Chugoku Cancer Center junior resident

Research Activities

Research Interests

免疫療法, 肺癌

Published Papers

  1. Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.
    Azuma K; Osuga M; Itoh S; Kawa Y; Kozuki T; Toi Y; Murotani K; Izumi M; Murata D; Hata A; Sugawara S; Satouchi M; Yamamoto N; Koh Y
    Cancer treatment and research communications  3, Feb. 2026 
  2. Soluble Immune Mediators Regulated by CD163+ Macrophages or CD8+ TILs According to EGFR Mutation Status During Anti-PD-1/L1 Monotherapy for NSCLC
    Daiki Murata; Koichi Azuma; Kenta Murotani; Akihiko Kawahara; Tomoaki Hoshino
    2026 
  3. Biomarker study on pneumonitis in durvalumab maintenance therapy after chemoradiotherapy for stage III non-small cell lung cancer
    Ryo Yano; Takaaki Tokito; Kenta Murotani; Daiki Murata; Shingo Tsuneyoshi; Hidenobu Ishii; Koichi Azuma; Tomoaki Hoshino
    BMC Cancer  19, Dec. 2025  , Refereed

MORE

Books etc

  1. - , Daiki Murata; Hidetoshi Hayashi , ドライバー遺伝子変異・転座陽性例の薬物療法─ROS1融合遺伝子，BRAF遺伝子V600E変異，MET遺伝子変異，RET融合遺伝子，NTRK融合遺伝子，KRAS遺伝子G12C変異，HER2遺伝子変異 , 医歯薬出版株式会社 , May. 2026
  2. - , Daiki Murata; Koichi Azuma , KRAS G12C変異陽性非小細胞肺癌に対する薬物療法 , 科学評論社 , Jul. 2025
  3. The cutting edge of immune checkpoint therapy , Daiki Murata; Koichi Azuma , 肺がん領域における最近のトピックス , 株式会社 北隆館 / 株式会社 ニュー・サイエンス社 , Apr. 2025

MORE

Conference Activities & Talks

  1. - , Daiki Murata , - , 11, Apr. 2026

MISC

  1. Antibiotics as a negative factor for Chemoimmunotherapy for non-small cell lung cancer with low PD-L1 expression , Tae Hata; Tadaaki Yamada; Yasuhiro Goto; Akihiko Amano; Takashi Kijima; Satoshi Watanabe; Naoki Furuya; Tomohiro Oba; Tatsuki Ikoma; Akira Nakao; Keiko Tanimura; Hirokazu Taniguchi; Akihiro Yoshimura; Tomoya Fukui; Daiki Murata; Koichi Takayama , CANCER SCIENCE , 117 , 325 , 325 , Jan. 2026
  2. Treatment options for NSCLC coexisting interstitial pneumonia with PD-L1-low-expressing: comparison of Chemo-IO and Chemo , 永田裕太郎; 笹田碧沙; 山田忠明; 畑妙; 後藤康洋; 天野明彦; 木島貴志; 渡部聡; 古屋直樹; 大場智広; 中尾明; 谷村恵子; 谷口寛和; 吉村彰紘; 福井朋也; 村田大樹; 解良恭一; 高山浩一 , 日本呼吸器学会誌(Web) , 14 , 2025
  3. Relationship between Immune-Related Adverse Events to Prognosis in PD-L1 1-49% Advanced Non-Small Cell Lung Cancer , 中尾明; 合田志穂; 山田忠明; 畑妙; 後藤康洋; 天野明彦; 木島貴志; 渡部聡; 古屋直樹; 大場智広; 生駒龍興; 谷村恵子; 谷口寛和; 吉村彰紘; 福井朋也; 村田大樹; 解良恭一; 高山浩一 , 日本呼吸器学会誌(Web) , 14 , 2025

MORE

Awards & Honors

  1. Apr. 2026, The Japanese Society of Internal Medicine, Encouragement Award of The Japanese Society of Internal Medicine
  2. Mar. 2024, WILEY, WILEY Top Downloaded Article（Thoracic Cancer）
  3. Jan. 2024, 日本内科学会, 第344回日本内科学会九州地方会 指導医賞

MORE